UBS Downgrades Ambu to Neutral, Citing Unrealistic Margin Targets

UBS has downgraded Danish medical device manufacturer Ambu A/S to “neutral” from “buy,” citing concerns that the company's long-term margin ambitions are unjustifiable. The investment bank also reduced its 12-month price target on the stock to 72 Danish crowns from 96 crowns.

Margin and Growth Forecasts Cut

The downgrade is rooted in UBS's more conservative outlook on Ambu's profitability. The brokerage now projects an adjusted EBIT margin of 15.7% for Ambu by 2028, significantly below the company management's target of approximately 20%. According to the UBS note, reaching the company's goal would necessitate an improbable margin expansion of over 550 basis points in fiscal years 2027-28 alone.

Reflecting this cautious view, UBS has lowered its earnings-per-share (EPS) estimates for Ambu for 2027 and 2028 by 7% and 12%, respectively. The bank also trimmed its growth forecasts, projecting a 14% compound annual growth rate (CAGR) for the Endoscopy Solutions division from 2026-2030, below management's guidance of over 15%.

Competitive Headwinds and Pipeline Concerns

UBS attributed its revised outlook to several key challenges facing the medical device maker. These include:

Ad

• Greater competitive pressure in the urology market, specifically from rivals Pusen and Verathon.
• A slow commercial ramp-up for its aScope 5 Ureteroscope, which was launched in late 2024.
• A product pipeline that is unlikely to contribute meaningfully to growth until the latter part of the decade.

Valuation Rationale

The reduction of the price target to 72 DKK is based on a discounted cash flow (DCF) model. UBS stated that roughly one-third of the cut was driven by its lower earnings forecasts. The remainder reflects a reduced terminal margin assumption of 19.5%, down from 22% previously.

Analysts at the bank concluded that Ambu's shares are unlikely to re-rate sustainably until its earnings expectations stabilize and the company demonstrates a consistent ability to meet or exceed its own financial targets.